The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 2, 2012, Pages 143-151

  Lilja, Mikael ^a,b   Rolandsson, Olov ^b   Norberg, Margareta ^b   Söderberg, Stefan ^b  

^a Jamtland County Council   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HEALTH SURVEY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SEX FACTORS; SWEDEN;

EID: 84858801195     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0123     Document Type: Article

References (36)

1. Ferrannini E, Camastra S. Relationship between impaired glucose tolerance, non-insulin-dependent diabetesmellitus and obesity. Eur J Clin Invest 1998;28(Suppl 2):3-6; discussion 6-7.
2. Cameron AJ, Boyko EJ, Sicree RA, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring) 2008;16:2707-2716.
3. Cameron AJ, Zimmet PZ, Söderberg S, et al. The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 2007;24:1460-1469.
4. Margetic S, Gazzola C, Pegg GG, et al. Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26:1407-1433.
5. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-175.
6. Hynes GR, Jones PJ. Leptin and its role in lipid metabolism. Curr Opin Lipidol 2001:12:321-327.
7. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8: 1288-1295.
8. Kieffer TJ, Habener JF. The adipoinsular axis: Effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000;278:E1-E14.
9. Matarese G, Sanna V, Lechler RI, et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 2002;51: 1356-1361.
10. McNeely MJ, Boyko EJ, Weigle DS, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care 1999;22:65-70.
11. Söderberg S, Zimmet P, Tuomilehto J, et al. Leptin predicts the development of diabetes in Mauritian men, but not women: A population-based study. Int J Obes (Lond) 1997;31:1126-1133.
12. Welsh P, Murray HM, Buckley BM, et al. Leptin predicts diabetes but not cardiovascular disease: Results from a large prospective study in an elderly population. Diabetes Care 2009;32:308-310.
13. Wannamethee SG, Lowe GD, Rumley A, et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007;30:1200-1205.
14. Thorand B, Zierer A, Baumert J, et al. Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: Results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med 2010;27:1004-1011.
15. Schmidt MI, Duncan BB, Vigo A, et al. Leptin and incident type 2 diabetes: Risk or protection? Diabetologia 2006;49: 2086-2096.
16. Snijder MB, Dekker JM, Bouter LM, et al. Comment on: Schmidt MI, Duncan BB, Vigo A, et al. (2006) Leptin and incident type 2 diabetes: Tisk or protection? Diabetologia 49:2086-2096. Diabetologia 2007;50:234-236; author reply 237-238; discussion 239-240.
17. Ley SH, Harris SB, Connelly PW, et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: The Sandy Lake Health and Diabetes Project. Diabetes Care 2008;31:1410-1415.
18. Norberg M, Stenlund H, Lindahl B, et al. Components of metabolic syndrome predicting diabetes: No role of inflammation or dyslipidemia. Obesity (Silver Spring) 2007;15:1875-1885.
19. Söderberg S, Stegmayr B, Stenlund H, et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004;256: 128-136.
20. Meyers MG Jr. Outstanding scientific award lecture 2010: Deconstructing leptin: From signals to circuits. Diabetes 2010;59:2708-2714.
21. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009;302:179-188.
22. Hivert MF, Sullivan LM, Shrader P, et al. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: The Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia 2011;54:1019-1024.
23. Zhuo Q, Wang Z, Fu P et al. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res Clin Pract 2009;84:27-33.
24. Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: A useful estimate of insulin resistance in patients with type 2 diabetes. J Endocrinol Invest 2010;33:514-518.
25. Finucane FM, Luan J, Wareham NJ, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 2009;52:2345-2349.
26. Hallmans G, Å gren Å , Johansson G, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions. Scand J Public Health 2003;31(Suppl 61):18-24.
27. Norberg M, Wall S, Boman K, et al. The Vä sterbotten Intervention Programme: Background, design and implications. Glob Health Action 2010;3:4643.
28. Franks PW, Rolandsson O, Debenham SL, et al. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 2008;51: 458-463.
29. Hallqvist J, Ahlbom A, Diderichsen F, et al. How to evaluate interaction between causes: A review of practices in cardiovascular epidemiology. J Intern Med 1996;239:377-382.
30. Lilja M, Rolandsson O, Shaw JE, et al. Higher leptin levels in Asian Indians than Creoles and Europids: A potential explanation for increased metabolic risk. Int J Obes (Lond) 2010;34:878-885.
31. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(Suppl 1):S152-S158.
32. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35:321-326.
33. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
34. Hajri T, Tao H, Wattacheril J, et al. Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-A and interleukin-6. Am J Physiol Endocrinol Metab 2011;300:E350-E360.
35. Zhang H, Zhang C. Adipose "talks" to distant organs to regulate insulin sensitivity and vascular function. Obesity (Silver Spring) 2010;18:2071-2076.
36. Buijsse B, Simmons RK, Griffin SJ, et al. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 2011;33:46-62.